1.Transarterial infusion chemotherapy combined with lipiodol chemoembolization for the treatment of advanced colorectal cancer
Xiaolong DING ; Shuai WANG ; Yaozhen MA ; Meipan YIN ; Tao LIU ; Shuiling JIN ; Xiaobing LI ; Chunxia LI ; Xinwei HAN ; Gang WU
Journal of Interventional Radiology 2024;33(2):186-190
Objective To discuss the clinical safety,feasibility and efficacy of transcatheter arterial infusion chemotherapy(TAI)combined with lipiodol chemoembolization in the treatment of advanced colorectal cancer(CRC).Methods The clinical data of 37 patients with advanced CRC,who received TAI combined with lipiodol chemoembolization at the First Affiliated Hospital of Zhengzhou University of China between June 2016 and December 2022,were retrospectively analyzed.The clinical efficacy was evaluated,the progression-free survival(PFS)and the serious complications were recorded.Results A total of 55 times of TAI combined with lipiodol chemoembolization procedures were successfully accomplished in the 37 patients.The mean used amount of lipiodol emulsion was 2.9 mL(0.8-10 mL).No serious complications such as bleeding and intestinal perforation occurred.The median follow-up time was 24 months(range of 3-48 months).The postoperative one-month,3-month,6-month and 12-month objective remission rates(ORR)were 67.6%(25/37),67.6%(25/37),64.9%(24/37)and 56.8%(21/37)respectively,and the postoperative one-month,3-month,6-month and 12-month disease control rates(DCR)were 91.9%(34/37),91.9%(34/37),89.2%(33/37)and 81.1%(30/37)respectively.The median PFS was 16 months(range of 2-47 months).As of the last follow-up,22 patients survived and 15 patients died of terminal stage of tumor.Conclusion Preliminary results of this study indicate that TAI combined with lipiodol chemoembolization is clinically safe and effective for advanced CRC,and it provide a new therapeutic method for patients with advanced CRC.
2.Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism
Junzhe CAI ; Songbai LIU ; Xiaobin FEI ; Peng LIU ; Changhao ZHU ; Xing WANG ; Yaozhen PAN
Journal of Clinical Hepatology 2024;40(5):989-996
ObjectiveTo investigate the effect of ankyrin-repeat domain-containing protein 22 (ANKRD22) on the proliferation, invasion, and migration of human hepatoma cells and its molecular mechanism. MethodsThe TCGA database was used to analyze the expression level of ANKRD22 in normal liver tissue and hepatocellular carcinoma tissue and its association with prognosis. Western Blot and qRT-PCR were used to measure the expression of ANKRD22 in human normal liver cells (L-02) and human hepatoma cells (Huh7, HepG2, MHCC-97H, SK-HEP-1, and SMMC-7721); CCK-8 assay, EdU, wound healing assay, and Transwell assay were used to observe the effect of ANKRD22 on the proliferation, invasion, and migration of hepatoma cells; Western Blot was used to investigate the association of ANKRD22 with cyclins and EMT-related proteins; KEGG and ssGSEA analyses were performed to investigate the mechanism of action of ANKRD22 in hepatoma cells, and related experiments were conducted for validation. The independent-samples t-test was used for comparison of continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. ResultsIn the TCGA database, the expression level of ANKRD22 in hepatoma tissue was significantly higher than that in normal liver tissue (t=5.083, P<0.05), and the patients with a high expression level of ANKRD22 had longer overall survival and disease-related survival than those with a low expression level of ANKRD22 (P<0.05). The expression level of ANKRD22 in various human hepatoma cell lines was higher than that in human normal liver cells (all P<0.05). Cell proliferation assay showed that the ANKRD22 overexpression group had significantly higher EdU positive rate and proliferation rate than the Vector group (t=19.60 and 6.72, both P<0.001), and compared with the si-NC group, the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower EdU positive rate and proliferation rate (all P<0.001). Compared with the Vector group, the overexpression group had significantly higher expression levels of Cyclin E1, Cyclin D1, CDK7, and CDK4 (t=3.54, 4.95, 6.34, and 5.19, all P<0.01), and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group (all P<0.001). The overexpression group had a significantly lower expression level of P27 than the Vector group (t=6.12, P<0.001), and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group (both P<0.001). Invasion and migration experiments showed that compared with the Vector group, the ANKRD22 overexpression group had significantly higher migration rate and number of crossings through the membrane (migration group and invasion group) (t=5.01, 25.60, and 3.67, all P<0.05), and compared with the si-NC group, thesi-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower migration rate and number of crossings through the membrane (migration group and invasion group) (all P<0.01). The overexpression group had significantly higher expression levels of N-cadherin, Vimentin, and Snail than the Vector group (t=12.13, 8.85, and 13.97, all P<0.001), and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group (all P<0.001); the overexpression group had a significantly lower expression level of E-cadherin than the Vector group (t=4.98, P<0.01), and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group (both P<0.001). The KEGG enrichment analysis and the ssGSEA analysis showed that ANKRD22 was associated with the PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma, and the overexpression group had significantly higher expression levels of p-AKT/AKT, p-PI3K/PI3K, and p-mTOR/mTOR than the Vector group (t=12.21, 3.43, and 9.75, all P<0.01), and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group (all P<0.001). ConclusionANKRD22 is highly expressed in hepatoma cells and can promote the proliferation, invasion, and migration of hepatoma cells and the activation of the PI3K/AKT/mTOR signaling pathway.
3.Progress on pharmaceutical characteristics of potassium-competitive acid blocker
Yaozhen WANG ; Can XU ; Shunli LV ; Jing TIAN ; Dongwei ZHANG
Journal of Pharmaceutical Practice and Service 2024;42(7):278-284
As a new class of acid inhibitors, potassium-competitive acid blocker(P-CAB) inhibits the conformational transition of H+, K+-ATPase with subsequent suppression of H+, K+ exchanging by binding reversibly near the K+ binding site of H+, K+-ATPase, which results in the inhibition of gastric acid secretion in a K+-competitive manner. The unique structure and novel mechanism of P-CAB contribute to the pharmaceutical characteristics superior to other PPIs, making it a new alternative for acid-related diseases(ARDs). Progress on pharmaceutical characteristics of P-CAB were reviewed in this paper.